Zai Lab Limited (ZLAB) Monday said China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib for the treatment of adults with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
In June last year, the drug was approved by the U.S. Food and Drug Administration (FDA) to treat patients aged 12 years and older with solid tumors that have a NTRK gene fusion. Repotrectinib is also approved by the FDA as well as NMPA for the treatment non-small-cell lung cancer.
Zai Lab has an exclusive license agreement with Turning Point Therapeutics, Inc.,a Bristol Myers Squibb company, to develop and sell repotrectinib in Greater China.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.